Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC

GlobeNewswire September 27, 2016

ProQR to Present at Scientific and Investor Conferences in September

GlobeNewswire September 6, 2016

ProQR Announces Results for the Second Quarter of 2016

GlobeNewswire August 17, 2016

ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis

GlobeNewswire July 19, 2016

ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC

GlobeNewswire June 21, 2016

Brainsway USA Announces Final Q1 2016 Results With Highest Sales and Revenue Growth in Company’s History

GlobeNewswire June 21, 2016

ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation

GlobeNewswire June 1, 2016

ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference

GlobeNewswire June 1, 2016

ProQR Announces Results for the First Quarter of 2016

GlobeNewswire May 18, 2016

ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting

GlobeNewswire April 25, 2016

ProQR Announces Annual Meeting of Shareholders

GlobeNewswire April 7, 2016

ProQR to Highlight a Growing Pipeline During a Research & Development Day and Present at the Barclays Global Healthcare Conference

GlobeNewswire March 1, 2016

ProQR Reports Q4 EPS E$(0.26) vs. Est. E$(0.39)

Press Releases February 17, 2016

comScore Reports Q4 Adj. Net Income $18.9M, GAAP EPS $(0.18), Sales $97.7M vs $98.9M Est.

Press Releases February 17, 2016

ProQR Announces Results for the Fourth Quarter and Full Year 2015

Press Releases February 17, 2016

What Vertex's Results Mean for Corbus, ProQR, and Nivalis

Accesswire February 16, 2016

ProQR to Present at the Leerink Partners Global Healthcare Conference

GlobeNewswire February 3, 2016

ProQR Announces R&D Day and Provides Update on Innovation Portfolio

GlobeNewswire November 30, 2015

ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials

GlobeNewswire November 23, 2015

ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences

GlobeNewswire October 1, 2015